NCT07430215

Impact of Disinfectant Caps on Nosocomial CLABSI

Not yet recruiting Last updated 25 February 2026

What this trial tests

trial testing use of desinfection caps in Central Line-associated Bloodstream Infections in 120 participants. Not yet recruiting.

Timeline

1 March 2026

Primary endpoint
30 September 2027

31 December 2027

Quick facts

Lead sponsor	BDH-Klinik Hessisch Oldendorf
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	120
Start date	1 March 2026
Primary completion	30 September 2027
Estimated completion	31 December 2027
Sites	1 location across Germany

Drugs / interventions tested

• use of desinfection caps
• sterile catheter cap

Conditions studied

• Central Line-associated Bloodstream Infections — all drugs for Central Line-associated Bloodstream Infections →

Sponsor

BDH-Klinik Hessisch Oldendorf

Who can join

Eligibility, any sex, with Central Line-associated Bloodstream Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In a worldwide, one-day, prospective point-prevalence study, a prevalence of 15.1% for hospital-acquired central line-associated bloodstream infections (HA-CLABSI) was determined in 13,796 patients across 1,265 intensive care units in 75 countries. According to reference data from the National Reference Center for Surveillance of Nosocomial Infections, an average of 1.2 HA-CLABSI episodes per 1,000 central venous catheter days occurred in German intensive care units between 2020 and 2024. Since the mean length of stay for the observed patients was 4 days, this value could be significantly higher for patients with longer stays, such as those undergoing neurological rehabilitation.

Besides economic consequences (costs of CLABSI treatment, extended treatment duration), bloodstream infections also have a significant impact on treatment outcomes. Studies show that patients have twice the mortality risk after a bloodstream infection - even after adjusting for disease severity - and that bloodstream infections are associated with longer stays in the intensive care unit and in the hospital.

Bloodstream infections occur when pathogenic germs enter the bloodstream. This can happen through entry via wounds (e.g., after trauma), via venous catheters (catheter-associated), or through other infections that spread systemically (e.g., infections in the lungs, abdomen, or urinary tract).

To reduce the risk of pathogenic germs entering the bloodstream from venous catheters via the access point, disinfection caps can be used. These caps are pre-treated with 70% isopropanol and packaged sterilely. According to an observational study, the use of such disinfection caps in an oncology clinic significantly reduced the rate of contaminated blood cultures (central venous catheters) from 2.5% (17 of 692) to 0.2% (1 of 470).

To reduce the risk of pathogenic germs entering the bloodstream from venous catheters, disinfection caps can be used. As part of quality-improvement measures, the use of disinfectant caps is planned in the neurological intensive care unit. The use of these caps therefore does not constitute a study intervention in the strict sense, but rather the implementation of a new in-house quality standard.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.